Role of alcohol and substances of abuse in the immunomodulation of human immunodeficiency virus disease: A review

Addictive Disorders and their Treatment

Volumn 3, Issue 4, 2004, Pages 174-182

  Goforth, Harold W ^a   Lupash, Daniel P ^b   Brown, Martha E ^c   Tan, Jun ^c,d   Fernandez, Francisco ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Neuroimmunology Laboratory   (United States)

Author keywords

Addiction; AIDS; Alcohol; Drug abuse; HIV; Immune regulation; Immunotoxicity

Indexed keywords

ALCOHOL; BUPRENORPHINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHEMOKINE RECEPTOR CCR5; COCAINE; CYTOKINE; DELTA OPIATE RECEPTOR; DRONABINOL; HOMOCOCAINE; INDINAVIR; INTERFERON; KAPPA OPIATE RECEPTOR; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NICOTINE; NICOTINIC AGENT; OPIATE; PLACEBO; POLYINOSINIC POLYCYTIDYLIC ACID; THYMIDINE KINASE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL ABUSE; ANOREXIA; ANTIBACTERIAL ACTIVITY; CACHEXIA; CHRONIC BRONCHITIS; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; ENZYME ACTIVITY; GLAUCOMA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOMODULATION; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG CARCINOMA; NARCOTIC DEPENDENCE; NAUSEA; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; OPIATE ADDICTION; OPPORTUNISTIC INFECTION; PAIN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TOBACCO; WASTING SYNDROME;

EID: 10644291065     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000137432.11895.ee     Document Type: Review

References (45)

1. Gisselquist D, Potterat JJ. Heterosexual transmission of HIV in Africa: an empiric estimate. Int J STD AIDS. 2003;14:162-173.
2. Douaihy AB, Jou RJ, Gorske T, et al. Triple diagnosis: dual diagnosis and HIV disease, Part 2. AIDS Read. 2003;13:375-382.
3. Nelson S, Kolls JK. Alcohol, host defence and society. Nat Rev Immunol. 2002;2:205-209.
4. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev. 2003;16:209-219.
5. Douaihy AB, Jou RJ, Gorske T, et al. Triple diagnosis: dual diagnosis and HIV disease, Part 1. AIDS Read. 2003;13:331-332, 339-341.
6. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev. 2003;16:209-219.
7. Taieb J, Delarche C, Ethuin F, et al. Ethanol-induced inhibition of cytokine release and protein degranulation in human neutrophils. J Leukoc Biol. 2002;72:1142-1147.
8. Wang X, Douglas SD, Metzger DS, et al. Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. Alcohol Clin Exp Res. 2002;26:1880-1886.
9. Hebert P, Pruett SB. Ethanol suppresses polyinosinic:polycytidylic acid-induced activation of natural killer cells primarily by acting on natural killer cells, not through effects on other cell types. Alcohol. 2002;28:75-81.
10. Prakash O, Tang ZY, Zhou P, et al. Ethanol decreases the efficiency of phosphorylation of thymidine kinase in a human T-lymphocytic cell line. Alcohol Clin Exp Res. 2002;26:295-302.
11. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol. 2003;36:242-252.
12. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832.
13. Sachithanandan S, Kay E, Leader M, et al. The effect of light drinking on HCV liver disease: the jury is still out. Biomed Pharmacother. 1997;51:295-297.
14. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730-739.
15. Ohta S, Watanabe Y, Nakajima T. Consumption of alcohol in the presence of hepatitis C virus is an additive risk for liver damage. Prev Med. 1998;27:461-469.
16. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc group. Hepatology. 1999;30:1054-1058.
17. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol. 1998;28:945-950.
18. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS. 2000;14:F17-F23.
19. Marmor M, Des Jarlais DC, Cohen H, et al. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS. 1987;1:39-44.
20. McCarthy L, Wetzel M, Sliker JK, et al. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001;62:111-123.
21. Gekker G, Lokensgard JR, Peterson PK. Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. Drug Alcohol Depend. 2001;64:257-263.
22. LeVier DG, Brown RD, Musgrove DL, et al. The effect of methadone on the immune status of B6C3F1 mice. Fundam Appl Toxicol. 1995;24:275-284.
23. Thomas PT, House RV, Bhargava HN. Direct cellular immunomodulation produced by diacetylmorphine (heroin) or methadone. Gen Pharmacol. 1995;26:123-130.
24. Carballo-Dieguez A, Sans J, Goetz R, et al. The effect of methadone on immunological parameters among HIV-positive and HIV-negative drug users. Am J Drug Alcohol Abuse. 1994;20:317-329.
25. Tubaro E, Santiangeli C, Belogi L, et al. Methadone vs morphine: comparison of their effect on phagocytic functions. Int J Immunopharmacol. 1987;9:79-88.
26. Tubaro E, Avico U, Santiangeli C, et al. Morphine and methadone impact on human phagocytic physiology. Int J Immunopharmacol. 1985;7:865-874.
27. Suboxone Prescribing Information. Viewed at http://www.suboxone.com/ Suboxone/pdfs/SuboxonePI. pdf. Accessed 26 October 2003.
28. Gomez-Flores R, Weber RJ. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology. 2000;48:145-156.
29. Marinol Prescribing Information. Viewed at http://www.marinol.com/pdf/ Marinol.pdf. Accessed 26 October 2003.
30. Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. 1998;5(6 Pt B):417-431.
31. Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther. 2002;95:203-220.
32. Klein TW, Friedman H, Specter S. Marijuana, immunity and infection. J Neuroimmunol. 1998;83:102-115.
33. Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396:141-149.
34. Nocerino E, Amato M, Izzo AA. Cannabis and cannabinoid receptors. Fitoterapia. 2000;71(Suppl 1):S6-S12.
35. Bredt BM, Higuera-Alhino D, Shade SB, et al. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol. 2002;42(Suppl 11):S82-S89.
36. Tashkin DR, Baldwin GC, Sarafian T, et al. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol. 2002;42(Suppl 11):S71-S81.
37. Shay AH, Choi R, Whittaker K, et al. Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. J Infect Dis. 2003;187:700-704.
38. Pacifici R, Fiaschi AI, Micheli L, et al. Immunosuppression and oxidative stress induced by acute and chronic exposure to cocaine in rat. Int Immunopharmacol. 2003;3:581-592.
39. Pirozhkov SV, Watson RR, Chen GJ. Ethanol enhances immunosuppression induced by cocaine. Alcohol Alcohol Suppl. 1993;2:75-82.
40. Sopori ML, Kozak W, Savage SM, et al. Nicotine-induced modulation of T cell function. Implications for inflammation and infection. Adv Exp Med Biol. 1998;437:279-289.
41. Bracci L, Lozzi L, Rustici M, et al. Binding of HIV-1 gp120 to the nicotinic receptor. FEBS Lett. 1992;311:115-118.
42. Bracci L, Ballas SK, Spreafico A, et al. Molecular mimicry between the rabies virus glycoprotein and human immunodeficiency virus-1 GP120: cross-reacting antibodies induced by rabies vaccination. Blood. 1997;90:3623-3628.
43. Giunta B, Fernandez F, Townsend K, et al. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Journal of Neuro-AIDS. under review.
44. Des Jarlais DC, Friedman SR. HIV and intravenous drug use. AIDS. 1988;2(Suppl 1):S65-S69.
45. Interventions to prevent HIV risk behaviors. NIH Consens Statement. 1997;15:1-41.